SEC Form 4 · accession 0001209191-17-047132
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, CFO & COO
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 31, 2017 | M | 2,125 | $83.36 | A | 118,013 | D | |
| Common StockF2,F3 | Jul 31, 2017 | S | 925 | $152.24 | D | 117,088 | D | |
| Common StockF3,F4 | Jul 31, 2017 | S | 1,100 | $153.30 | D | 115,988 | D | |
| Common Stock | Jul 31, 2017 | S | 100 | $154.13 | D | 115,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $83.36 | Jul 31, 2017 | M | 2,125 | D | — | Jul 29, 2023 | Common Stock | 2,125 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $152.24 (range $151.80 to $152.79).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $153.30 (range $152.96 to $153.72).
- F5Fully vested.